AU2003275948A8 - Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides - Google Patents

Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides

Info

Publication number
AU2003275948A8
AU2003275948A8 AU2003275948A AU2003275948A AU2003275948A8 AU 2003275948 A8 AU2003275948 A8 AU 2003275948A8 AU 2003275948 A AU2003275948 A AU 2003275948A AU 2003275948 A AU2003275948 A AU 2003275948A AU 2003275948 A8 AU2003275948 A8 AU 2003275948A8
Authority
AU
Australia
Prior art keywords
polypeptides
protein
pharmaceutical composition
tissue factor
factor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003275948A
Other versions
AU2003275948A1 (en
Inventor
Jakob Michael Back
Christian Meyer
Lars Christian Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003275948A8 publication Critical patent/AU2003275948A8/en
Publication of AU2003275948A1 publication Critical patent/AU2003275948A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003275948A 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides Abandoned AU2003275948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201709 2002-11-06
DKPA200201709 2002-11-06
PCT/DK2003/000752 WO2004041296A2 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides

Publications (2)

Publication Number Publication Date
AU2003275948A8 true AU2003275948A8 (en) 2004-06-07
AU2003275948A1 AU2003275948A1 (en) 2004-06-07

Family

ID=32309251

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003275948A Abandoned AU2003275948A1 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides

Country Status (2)

Country Link
AU (1) AU2003275948A1 (en)
WO (1) WO2004041296A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064870A2 (en) * 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
BR112012031727B1 (en) 2010-06-15 2022-03-29 Genmab A/S DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION, AND, USE OF DRUG-ANTIBODY CONJUGATE
EP2869833B1 (en) * 2012-07-04 2018-04-04 ZZ Biotech LLC. Activated protein c for use in the treatment of inflammatory skin disorders
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263943A1 (en) * 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives

Also Published As

Publication number Publication date
WO2004041296A2 (en) 2004-05-21
WO2004041296A3 (en) 2004-07-29
AU2003275948A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
AU2003252478A1 (en) Ccr4 antagonist and medicinal use thereof
AU2003228809A8 (en) Kinase anchor protein muteins, peptides thereof, and related methods
IL168049A0 (en) Interferon- alpha polypeptides and conjugates
IL165499A (en) Vpac2 receptor agonist polypeptides, pharmaceutical compositions comprising them and uses thereof
EP1652855A4 (en) Polypeptides having brain -localizing activity and uses thereof
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
EP1536813A4 (en) Compositions and methods comprising protein activated receptor antagonists
AU2003234734A8 (en) Peptide antagonists of tgf-beta family members and therapeutic uses thereof
IL207422A0 (en) Improved recombinant human interferon-beta-ib polypeptides
HUP0402318A3 (en) Pharmaceutical composition comprising cyclosporin and use thereof
HUP0400976A3 (en) Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides
AU2003275948A8 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
AU2003226899A8 (en) Human diabetes-mediating proteins
IL161544A0 (en) Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides
SI1482967T1 (en) Pharmaceutical and cosmetic compositions comprising plgf-1
EP1582586A4 (en) Apoptosis-associated protein and use thereof
EP1581250A4 (en) Oral formulations for proteins and polypeptides
EP1499345A4 (en) Protein a compositions and methods of use
EP1541677A4 (en) Novel proteins and use thereof
EP1577322A4 (en) Novel proteins and use thereof
IL135442A0 (en) Peptides and pharmaceutical compositions comprising them
AU2002245311A8 (en) Human protein kinase n-like polypeptide and uses thereof
IL161523A0 (en) Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
ZA200509672B (en) A pharmaceutical composition comprising a P2X7-receptor antagonist and a tumour necrosis factor ?
AU2003213933A8 (en) Purified polypeptides involved in protein synthesis and modification

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase